Nonneutralizing human antibody fragments against hepatitis C virus E2 glycoprotein modulate neutralization of binding activity of human recombinant Fabs.
about
Human monoclonal antibody-based therapy in the treatment of invasive candidiasisMapping B-cell epitopes of hepatitis C virus E2 glycoprotein using human monoclonal antibodies from phage display librariesInhibition of Hepatitis C Virus Nonstructural Protein, Helicase Activity, and Viral Replication by a Recombinant Human Antibody CloneIdentification of a Broadly Cross-Reacting and Neutralizing Human Monoclonal Antibody Directed against the Hepatitis C Virus E2 ProteinHepatitis C Virus (HCV) Infection May Elicit Neutralizing Antibodies Targeting Epitopes Conserved in All Viral GenotypesDiscrete conformations of epitope II on the hepatitis C virus E2 protein for antibody-mediated neutralization and nonneutralizationHuman monoclonal antibodies to a novel cluster of conformational epitopes on HCV E2 with resistance to neutralization escape in a genotype 2a isolateBinding of the hepatitis C virus E2 glycoprotein to CD81 is strain specific and is modulated by a complex interplay between hypervariable regions 1 and 2.Intracytoplasmic stable expression of IgG1 antibody targeting NS3 helicase inhibits replication of highly efficient hepatitis C Virus 2a clone.Recombinant antibodies for diagnostics and therapy against pathogens and toxins generated by phage display.Neutralization interfering antibodies: a "novel" example of humoral immune dysfunction facilitating viral escape?Molecular signatures of hepatitis C virus (HCV)-induced type II mixed cryoglobulinemia (MCII).Cooperativity in virus neutralization by human monoclonal antibodies to two adjacent regions located at the amino terminus of hepatitis C virus E2 glycoproteinChimeric antigen receptor (CAR)-engineered T cells redirected against hepatitis C virus (HCV) E2 glycoprotein.Multiantibody strategies for HIV.Structural and antigenic definition of hepatitis C virus E2 glycoprotein epitopes targeted by monoclonal antibodies.A Biologically-validated HCV E1E2 Heterodimer Structural Model.Divergent Trends of Anti-JCPyV Serum Reactivity and Neutralizing Activity in Multiple Sclerosis (MS) Patients during Treatment with Natalizumab.Amino acid residue-specific neutralization and nonneutralization of hepatitis C virus by monoclonal antibodies to the E2 protein.
P2860
Q26864291-F98D51D2-CE9F-4744-A394-A2B5DD19A305Q27469875-D980EF30-9677-4FBA-8584-BC7B4D78A69FQ27477552-BD7CC736-7A11-4500-9090-E40329BED34AQ27485318-A9B1AD87-5CC4-47BE-BF3C-D90850644BD0Q27490450-869A5512-4192-4EAB-B736-97F0CE6E5287Q27684579-0B3A7532-7E0D-4A1C-A57A-EEFA49F83D7BQ28482261-B7019BF2-7853-438A-82A9-96C8EA379745Q29048140-7AD1E42A-199D-488E-81EE-F1B0325CA34DQ33991988-27F4DE12-0947-4044-97BC-8A68444D5BA4Q36023082-C8F2EAA6-C074-490F-AD88-AABB0E9239E7Q36404194-2873DA6F-2393-439C-978B-F8AB04604DD5Q36432725-D21B61B3-AE34-4844-B706-505947F85C4CQ36506935-FAA2ACF8-628A-4CC4-A151-BCCDA766392EQ36682313-F80B2B81-BB5F-4EB0-BF70-6CE026752B22Q38120526-4D09F2F0-3C93-4A8F-AAFF-01B134619626Q38128299-511F23C0-6748-404A-90FC-17A6DBBC531DQ40288437-1D2CCBD6-4C4C-44D6-9232-1A00357F70EBQ40761630-102426FB-6306-492D-B432-E6E555CF2151Q41168118-328EE335-9E7F-408D-AC9A-239939880E24
P2860
Nonneutralizing human antibody fragments against hepatitis C virus E2 glycoprotein modulate neutralization of binding activity of human recombinant Fabs.
description
2001 nî lūn-bûn
@nan
2001 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Nonneutralizing human antibody ...... ity of human recombinant Fabs.
@ast
Nonneutralizing human antibody ...... ity of human recombinant Fabs.
@en
type
label
Nonneutralizing human antibody ...... ity of human recombinant Fabs.
@ast
Nonneutralizing human antibody ...... ity of human recombinant Fabs.
@en
prefLabel
Nonneutralizing human antibody ...... ity of human recombinant Fabs.
@ast
Nonneutralizing human antibody ...... ity of human recombinant Fabs.
@en
P2093
P50
P356
P1433
P1476
Nonneutralizing human antibody ...... vity of human recombinant Fabs
@en
P2093
P356
10.1006/VIRO.2001.1014
P407
P50
P577
2001-09-01T00:00:00Z